About this episode

The episode discusses the benefits of extending dual antiplatelet therapy beyond 12 months for selected patients with multivessel coronary artery disease.

🫀 Should dual antiplatelet therapy continue beyond 12 months? The DAPT-MVD trial (NEJM 2026) suggests that carefully selected patients with multivessel coronary artery disease who remain event-free after one year of therapy may benefit from another 12 months of clopidogrel plus aspirin . The result? Fewer cardiovascular events—driven largely by fewer myocardial infarctions— without more clinically relevant bleeding in this low-bleeding-risk cohort. ⚖️ A timely reminder that the future of DAPT lies in precision patient selection , not a one-size-fits-all approach. 🩺📚 #Cardiology #DAPT #MedicalEducation #MedicalPodcasts #NEJM

People in this episode

Host: Dr RR Baliga

Topics covered

• dual antiplatelet therapy
• cardiology
• precision medicine
• cardiovascular events
• myocardial infarction
• medical education

Keywords

• DAPT
• cardiology
• clopidogrel
• aspirin
• myocardial infarction
• bleeding risk
• medical education
• NEJM

Mentioned in this episode

Organizations: DAPT-MVD trial, NEJM

Products: clopidogrel, aspirin

Places: multivessel coronary artery disease

More episodes of Dr RR Baliga's "Got Knowledge Doc" Podkast

• Great Doctors Series: Zhang Zhongjing—China's Medical Sage · July 21, 2026 · 2 min
• 🩺 Can dual antithrombotic therapy after PCI be safely shortened to just 1 month in patients with atrial fibrillation? · July 20, 2026 · 3 min
• 🛡️ Fountain of Youth, Immune Truth: EP2 Flips the Healthy Aging Switch · July 18, 2026 · 2 min
• 🍏 Whole Fruit Wins: Rethinking Fructose and Blood Pressure · July 17, 2026 · 2 min
• 🧠 Blood p-Tau217: 🩸 A Blood Test That Sees Dementia Coming · July 16, 2026 · 2 min
• Thymus Matters: Cancer, Cardiovascular Risk, Survival ❤️ · July 15, 2026 · 3 min

Explore listener stats, chart rankings, contacts and more on the Dr RR Baliga's "Got Knowledge Doc" Podkast podcast page.